Clinical Trial

A Study to Evaluate the Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 11, 2026 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, observer-blinded, placebo-controlled Phase Ⅱ clinical trial to evaluate the immunogenicity and safety of the Respiratory Syncytial Virus (RSV) Vaccine, LYB005 in participants aged 60 years and older.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-27.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-02-06
Trial Details
NCT Number NCT07208461
Lead Sponsor Guangzhou Patronus Biotech Co., Ltd.
Conditions Respiratory Syncytial Virus Infection Prevention
Enrollment 700 participants
Start Date 2025-10-21
Primary Completion 2026-03 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-11